| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Compass Therapeutics, Inc. (NASDAQ: CMPX) is a clinical-stage biopharmaceutical company pioneering innovative antibody-based therapeutics to combat cancer. Headquartered in Boston, Massachusetts, Compass focuses on developing bispecific and monoclonal antibodies targeting critical pathways in tumor biology, such as angiogenesis and immune checkpoint modulation. Its lead candidates include CTX-009, a bispecific antibody inhibiting Delta-like ligand 4/Notch and VEGF-A signaling, and CTX-471, a CD137 agonist designed to enhance anti-tumor immune responses. The company also explores CTX-8371, a PD-1/PD-L1 bispecific inhibitor, positioning itself at the forefront of immuno-oncology research. With no commercialized products yet, Compass relies on strategic collaborations and funding to advance its pipeline. Operating in the high-growth biotechnology sector, the company aims to address unmet needs in oncology, leveraging cutting-edge science to improve patient outcomes.
Compass Therapeutics presents a high-risk, high-reward opportunity for investors focused on early-stage biotech innovation. The company’s pipeline targets validated oncology pathways with novel mechanisms, including angiogenesis inhibition (CTX-009) and immune activation (CTX-471). However, as a pre-revenue entity with a net loss of $42.5 million in FY2023 and negative operating cash flow, its valuation hinges entirely on clinical success. The stock’s beta of 1.19 reflects volatility typical of developmental biotech firms. Key risks include trial failures, cash burn ($24.2 million in reserves as of FY2023), and competition in crowded spaces like PD-1/PD-L1. Upside potential lies in positive Phase 2 data for CTX-009 in biliary tract cancer and strategic partnerships. Investors should monitor trial milestones and funding runway closely.
Compass Therapeutics operates in the highly competitive immuno-oncology (IO) space, where it differentiates through bispecific antibody engineering. Its lead asset, CTX-009, combines anti-angiogenic (VEGF-A/DLL4) and immune-modulating (CD137) mechanisms—a niche approach compared to single-pathway inhibitors like Regeneron’s aflibercept (VEGF trap) or AstraZeneca’s DLL4-targeting navicixizumab. However, the DLL4/Notch space is contested by companies like OncoMed Pharmaceuticals (acquired by Mereo BioPharma). CTX-471 faces stiff competition from other CD137 agonists, including Bristol Myers Squibb’s urelumab and Pfizer’s utomilumab, though Compass’s IgG4 design may offer better safety. The PD-1/PD-L1 bispecific CTX-8371 enters a saturated market dominated by Keytruda (Merck) and Opdivo (BMS), requiring superior efficacy to gain traction. Compass’s small size limits commercialization capabilities, necessitating partnerships. Its competitive edge lies in modular antibody platforms and focused pipeline, but scalability and clinical validation remain critical hurdles.